{"doi":"10.1093/ofid/ofad500.563","title":"494. Real-world effectiveness of tixagevimab/cilgavimab for COVID-19 pre-exposure prophylaxis in solid organ transplant recipients during the Omicron variant period","abstract":"Abstract Background Pre-exposure prophylaxis (PrEP) with a combination of long-acting monoclonal antibodies with tixagevimab/cilgavimab (T/C) have provided viral neutralizing activity against SARS-CoV-2 and protected solid organ transplant recipients (SOTRs) that produced poor immunogenicity after COVID-19 immunization. However, real-world data on the effectiveness and safety of T/C in SOTRs during the Omicron wave is limited. Methods A prospective study at a single transplant center was conducted to evaluate the effectiveness and adverse events (AE) of T/C among SOTRs during the BA.2.75 Omicron lineages period (August 2022 to February 2023). T/C of 150/150 and 300/300 mg doses were provided from August 2022 to December 2022 and after, respectively. Results A total of 39 SOTRs comprising kidney (n= 29), liver (n=2), and heart (n=8) transplant recipients were included in the study. Thirty-three (85%) and 6 (15%) SOTRs received 150/150 and 300/300 mg of T/C, respectively. The median (IQR) age was 52 (35-62) years. Twenty-two (56%) had a prior history of COVID-19. The median (IQR) number of COVID-19 vaccine was 4 (3-4) doses. During the median follow-up of 6.35 (5-8.33) months, COVID-19 developed in 5 (12.8%) out of 39 SOTRs with a median (IQR) time of 73 (36-115) days from receiving T/C. None of those who received a 300/300 mg dose developed COVID-19. There was no severe COVID-19 or death observed. Five (12.8%) SOTRs reported mild and reversible AEs with pain at injection (n=2), fever (n=3), and muscle aches (n=1). There was no allograft rejection reported. Conclusion Breakthrough SARS-CoV-2 infection remains among fully vaccinated SOTRs receiving T/C as PrEP and subjects to concurrent circulating strain in the community. However, the disease severity appears mild, and the short-term safety profile seems tolerable. Disclosures All Authors: No reported disclosures","journal":"Open Forum Infectious Diseases","year":2023,"id":414375,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8968,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":36862,"name":"Sasisopin Kiertiburanakul","orcid":"0000-0003-4379-4704","position":1,"is_corresponding":false},{"id":1196086,"name":"Sarinya Boongird","orcid":"0000-0002-3194-1511","position":2,"is_corresponding":false},{"id":1196401,"name":"Napan Sutharattanapong","orcid":null,"position":3,"is_corresponding":false},{"id":1196087,"name":"Teerapat Yingchoncharoen","orcid":"0000-0001-5689-2704","position":4,"is_corresponding":false},{"id":1196088,"name":"Abhasnee Sobhonslidsuk","orcid":"0000-0002-3730-5532","position":5,"is_corresponding":false},{"id":1196089,"name":"Jackrapong Bruminhent","orcid":"0000-0003-0930-8936","position":6,"is_corresponding":false},{"id":1196400,"name":"Gun Rojanakit","orcid":null,"position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T01:22:05.177070Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}